¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : À¯Çüº°, Á¦Á¦ À¯Çüº°, ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)
Global Pentavalent Market Size Study & Forecast, by Type, by Formulation Type, by Application and Regional Analysis, 2023-2030
»óǰÄÚµå
:
1300767
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2023³â 06¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ 5°¡¹é½Å ½ÃÀåÀº 2022³â¿¡ ¾à 24¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 5.1% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
5°¡¹é½ÅÀº µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ, ÆÄ»ódz, BÇü °£¿°, Hib(Haemophilus influenzae type b)ÀÇ 5 Á¾·ù Áúº´À» ¿¹¹æÇÏ´Â ¹é½ÅÀÔ´Ï´Ù. 1ȸ ÁÖ»ç·Î 5 Á¾·ùÀÇ ¹é½ÅÀ» Á¢Á¾ÇÒ ¼ö ÀÖÀ¸¹Ç·Î '5°¡' ¹é½ÅÀ¸·Î ºÒ¸®°í ÀÖ½À´Ï´Ù. 5°¡¹é½Å ½ÃÀåÀº Á¤ºÎ ±¸»óÀÇ Áõ°¡, ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ Áõ°¡, ÀÇ·á ÁöÃâÀÇ Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ È®´ëÇϰí ÀÖ½À´Ï´Ù.
µðÇÁÅ׸®¾Æ´Â È£ÈíÀ̳ª ½Ä»ç¿¡ ½É°¢ÇÑ ÁöÀåÀ» ÃÊ·¡Çϸç, ÇǺΠ±Ë¾çÀÇ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. 5°¡¹é½ÅÀÇ 3ȸ Á¢Á¾ ½ºÄÉÁÙÀº ¾î¸°À̸¦ µðÇÁÅ׸®¾Æ·ÎºÎÅÍ º¸È£ÇÕ´Ï´Ù. ±× °á°ú, µðÇÁÅ׸®¾Æ°¡ ´õ ÈçÇØÁö¸é¼ 5°¡¹é½ÅÀÇ ¼ö¿ä°¡ ±ÞÁõÇß½À´Ï´Ù. ÀÌ¿Í °°ÀÌ µðÇÁÅ׸®¾ÆÀÇ À¯º´·ü »ó½ÂÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é IHR(International Health Regulations)ÀÇ º¸°í ÇÁ·Î¼¼½º¿¡¼´Â 2022³â¿¡ ÁÖ·Î 6¿ù°ú 8¿ù¿¡ µðÇÁÅ׸®¾ÆÀÇ º¸°í °Ç¼ö°¡ ¸Å¿ì ¸¹¾Ò´ø °ÍÀÌ ±â·ÏµÇ¾î ÀÖ½À´Ï´Ù. ½ºÀ§½º¿¡ º»ºÎ¸¦ µÐ UN Àü¹® ±â°üÀÎ ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 7°³±¹À¸·ÎºÎÅÍ 144¸íÀÇ µðÇÁÅ׸®¾Æ Áõ·Ê°¡ º¸°íµÇ°í ÀÖÀ¸¸ç, ´Ù¼ö´Â ³¹ÎÀ̾ú½À´Ï´Ù. 144¸í Áß 44¸í(31%)ÀÌ °Ë»ç½Ç¿¡¼ÀÇ È®Àο¡ ÀÇÇØ µ¶¼Ò¿ø¼º µðÇÁÅ׸®¾Æ·Î ÆÇ¸í, 97¸í(69%)ÀÌ ÀÓ»óÀûÀ¸·Î ÀûÇÕ, 3¸í(2%)ÀÌ ÀÇ½É »ç·Ê¿´½À´Ï´Ù. ±× °á°ú, µðÇÁÅ׸®¾Æ ¹ß»ýÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ½ÃÀåÀº È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû ±¸»óÀÇ Áõ°¡ ¹× 5°¡¹é½Å °³¹ß Ȱµ¿¿¡ ´ëÇÑ ¿¬±¸°³¹ßºñÀÇ Áõ°¡°¡ ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀåÀ» ÃÊ·¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª 5°¡¹é½Å °³¹ßÀÇ ³ôÀº Ãʱ⠺ñ¿ë°ú ³·Àº ÀÎÁöµµ°¡°¡ 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå Á¶»ç¿¡¼ °í·ÁÇÑ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ ¿ìÀ§¼º, ÀÌ Áö¿ªÀÇ Áúȯ À¯º´·ü Áõ°¡, ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚÀÇ Áõ°¡¿¡ ÀÇÇØ 2022³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À̰ÍÀº ½ÅÈï ½ÃÀåÀÇ ¹ßÀü, ¹é½Å °³¹ßÀ» À§ÇÑ °øµ¿ ¿¬±¸ °Ç¼öÀÇ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ªÀû È®´ë, Á¤ºÎ±â°ü ¹× ºñ¿µ¸®´ÜüÀÇ ½ÃÀå Âü¿© µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.
º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ¸®Æ÷Æ®´Â Á¶»ç ´ë»ó±¹ »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½Ã۵µ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× ½ÃÀå ±¸µµÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå ½º³À¼ô
- ¼¼°è ½ÃÀ塤ºÎ¹®º° ½ÃÀå Ã߻ꡤ¿¹Ãø, 2020-2030³â
- 5°¡¹é½Å ½ÃÀå : Áö¿ªº°, 2020-2030³â
- 5°¡¹é½Å ½ÃÀå : À¯Çüº°, 2020-2030³â
- 5°¡¹é½Å ½ÃÀå : Á¦Á¦ À¯Çüº°, 2020-2030³â
- 5°¡¹é½Å ½ÃÀå : ¿ëµµº°, 2020-2030³â
- ÁÖ¿ä µ¿Çâ
- Á¶»ç ¹æ¹ý
- Á¶»ç ÀüÁ¦Á¶°Ç
Á¦2Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ´ë»ó³â
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå ¿ªÇÐ
- 5°¡¹é½Å ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
- ½ÃÀå ÃËÁø¿äÀÎ
- µðÇÁÅ׸®¾Æ À¯º´·üÀÇ »ó½Â
- ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ Áõ°¡
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- 5°¡¹é½Å °³¹ßÀÇ Ãʱ⠰íºñ¿ë
- Ä¡·á¹ý¿¡ °üÇÑ ÀνÄÀÇ ºÎÁ·
- ½ÃÀå ±âȸ
- 5°¡¹é½Å °³¹ß Ȱµ¿¿¡ ´ëÇÑ ¿¬±¸°³¹ßºñÀÇ Áõ°¡
- ÁÖ¿ä ½ÃÀå ±â¾÷¿¡ ÀÇÇÑ Àü·«Àû ±¸»óÀÇ Áõ°¡
Á¦4Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's 5 Force ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's 5 Force ¿µÇ⠺м®
- PEST ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- COVID-19 ¿µÇ⠺м®
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È
Á¦5Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : À¯Çüº°
- ½ÃÀå ½º³À¼ô
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : À¯Çüº°, ¼º´Éº°, ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- 5°¡¹é½Å ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- Sodium Stibogluconate
- Meglumine Antimoniate
Á¦6Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : Á¦Á¦ À¯Çüº°
- ½ÃÀå ½º³À¼ô
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : Á¦Á¦ À¯Çüº°, ¼º´É - ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : Á¦Á¦ À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- 5°¡¹é½Å ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
Á¦7Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : ¿ëµµº°
- ½ÃÀå ½º³À¼ô
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : ¿ëµµº° ½ÇÀû¡¤ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå, ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- 5°¡¹é½Å ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦8Àå ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå : Áö¿ªº° ºÐ¼®
- ÁÖ¿ä ±¹°¡
- ÁÖ¿ä ½ÅÈï ±¹°¡
- ¼¼°èÀÇ 5°¡¹é½Å ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
- ºÏ¹Ì
- ¹Ì±¹
- À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- Á¦Á¦ À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ij³ª´Ù
- À¯·´ÀÇ 5°¡¹é½Å ½ÃÀå ½º³À¼ô
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ 5°¡¹é½Å ½ÃÀå ½º³À¼ô
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ 5°¡¹é½Å ½ÃÀå ½º³À¼ô
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Sanofi
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¸§)
- Á¦Ç° °³¿ä
- ÃÖ±Ù µ¿Çâ
- GlaxoSmithKline PLC.
- Bristol-Myers Squibb Company
- Maiden Pharmaceuticals Limited
- Shandong Xinhua Pharmaceutical Co.,Ltd.
- Panacea Biotec Ltd.
- Biological E. Ltd.
- Novartis AG
- Shantha Biotechnics Ltd.
- Serum Institute of India Pvt. Ltd.
Á¦10Àå Á¶»ç ÇÁ·Î¼¼½º
- Á¶»ç ÇÁ·Î¼¼½º
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
- Á¶»ç ÀüÁ¦Á¶°Ç
KSA
¿µ¹® ¸ñÂ÷
Global Pentavalent Market is valued at approximately USD 2.43 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5.1% over the forecast period 2023-2030. Pentavalent is a kind of vaccine that protects against five different diseases: diphtheria, pertussis (whooping cough), tetanus, hepatitis B, and Haemophilus influenzae type b (Hib). It is called a "pentavalent" vaccine as it contains five different vaccines in one shot. The Pentavalent Market is expanding because of factors such as increasing government initiatives, increasing number of immunization programs, and rising healthcare expenditure.
Diphtheria results in serious difficulties breathing and eating, as well as the potential for skin ulcers. The three-dose schedule of the pentavalent vaccine protects children from diphtheria diseases; as a result, demand for pentavalent vaccines soared as diphtheria became more common. Thus, the rising prevalence of diphtheria is driving the market growth. For instance, the International Health Regulations (IHR) reporting process recorded an unusually high number of reported cases of diphtheria in 2022, primarily in the months of June and August. According to the World Health Organization, a specialized agency of the United Nations with headquarters in Switzerland. 144 cases of diphtheria have been reported from seven different countries, many of whom were refugees. Among 144 individuals, 44 (31%) were found to have toxigenic diphtheria by laboratory confirmation, 97 (69%) were found to be clinically compatible, and 3 (2%), suspected instances. As a result, the market is expanding because of the increasing occurrence of diphtheria. In addition, increasing strategic initiatives by the key market players and growing R&D spending on pentavalent vaccine development activities is creating lucrative growth in the market. However, the high initial cost of pentavalent development and lack of awareness stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Pentavalent Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players and the region's increasing disease prevalence, and rising investment in research and development activities. Asia Pacific is expected to grow at the highest CAGR during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for vaccine development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.
Major market players included in this report are:
- Sanofi
- GlaxoSmithKline PLC.
- Bristol-Myers Squibb Company
- Maiden Pharmaceuticals Limited
- Shandong Xinhua Pharmaceutical Co.,Ltd.
- Panacea Biotec Ltd.
- Biological E. Ltd.
- Novartis AG
- Shantha Biotechnics Ltd.
- Serum Institute of India Pvt. Ltd.
Recent Developments in the Market:
- In December 2022, The United States Food and Drug Administration, a US federal agency of the Department of Health and Human Services, approved Pfizer's Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY in Adolescents), which is indicated for the prevention of meningococcal disease in people aged 10 to 25.
- In January 2022, Ardian, a private equity investment firm with headquarters in France, acquired Biofarma Group. Ardian would be able to facilitate the market's further international expansion and consolidation with this acquisition. The Biofarma Group is an Italian business that competes in the market for pentavalent vaccines.
Global Pentavalent Market Report Scope:
- Historical Data: 2020 - 2021
- Base Year for Estimation: 2022
- Forecast period: 2023-2030
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: Type, Formulation Type, Application, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
- Sodium Stibogluconate
- Meglumine Antimoniate
By Type:
By Application:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Pentavalent Market, by Region, 2020-2030 (USD Billion)
- 1.2.2. Pentavalent Market, by Type, 2020-2030 (USD Billion)
- 1.2.3. Pentavalent Market, by Formulation Type, 2020-2030 (USD Billion)
- 1.2.4. Pentavalent Market, by Application, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Pentavalent Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Pentavalent Market Dynamics
- 3.1. Pentavalent Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Rising prevalence of diphtheria
- 3.1.1.2. Increasing number of immunization programs
- 3.1.2. Market Challenges
- 3.1.2.1. High initial cost of pentavalent development
- 3.1.2.2. Lack of awareness regarding treatment availability
- 3.1.3. Market Opportunities
- 3.1.3.1. Growing R&D spending on pentavalent vaccine development activities
- 3.1.3.2. Increasing strategic initiatives by the key market players
Chapter 4. Global Pentavalent Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Pentavalent Market, by Type
- 5.1. Market Snapshot
- 5.2. Global Pentavalent Market by Type, Performance - Potential Analysis
- 5.3. Global Pentavalent Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
- 5.4. Pentavalent Market, Sub Segment Analysis
- 5.4.1. Sodium Stibogluconate
- 5.4.2. Meglumine Antimoniate
Chapter 6. Global Pentavalent Market, by Formulation Type
- 6.1. Market Snapshot
- 6.2. Global Pentavalent Market by Formulation Type, Performance - Potential Analysis
- 6.3. Global Pentavalent Market Estimates & Forecasts by Formulation Type 2020-2030 (USD Billion)
- 6.4. Pentavalent Market, Sub Segment Analysis
- 6.4.1. Lyophilized
- 6.4.2. Liquid
Chapter 7. Global Pentavalent Market, by Application
- 7.1. Market Snapshot
- 7.2. Global Pentavalent Market by Application, Performance - Potential Analysis
- 7.3. Global Pentavalent Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
- 7.4. Pentavalent Market, Sub Segment Analysis
- 7.4.1. Hospitals Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Online Pharmacies
Chapter 8. Global Pentavalent Market, Regional Analysis
- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Pentavalent Market, Regional Market Snapshot
- 8.4. North America Pentavalent Market
- 8.4.1. U.S. Pentavalent Market
- 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
- 8.4.1.2. Formulation Type breakdown estimates & forecasts, 2020-2030
- 8.4.1.3. Application breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Pentavalent Market
- 8.5. Europe Pentavalent Market Snapshot
- 8.5.1. U.K. Pentavalent Market
- 8.5.2. Germany Pentavalent Market
- 8.5.3. France Pentavalent Market
- 8.5.4. Spain Pentavalent Market
- 8.5.5. Italy Pentavalent Market
- 8.5.6. Rest of Europe Pentavalent Market
- 8.6. Asia-Pacific Pentavalent Market Snapshot
- 8.6.1. China Pentavalent Market
- 8.6.2. India Pentavalent Market
- 8.6.3. Japan Pentavalent Market
- 8.6.4. Australia Pentavalent Market
- 8.6.5. South Korea Pentavalent Market
- 8.6.6. Rest of Asia Pacific Pentavalent Market
- 8.7. Latin America Pentavalent Market Snapshot
- 8.7.1. Brazil Pentavalent Market
- 8.7.2. Mexico Pentavalent Market
- 8.8. Middle East & Africa Pentavalent Market
- 8.8.1. Saudi Arabia Pentavalent Market
- 8.8.2. South Africa Pentavalent Market
- 8.8.3. Rest of Middle East & Africa Pentavalent Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Sanofi
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Recent Developments
- 9.3.2. GlaxoSmithKline PLC.
- 9.3.3. Bristol-Myers Squibb Company
- 9.3.4. Maiden Pharmaceuticals Limited
- 9.3.5. Shandong Xinhua Pharmaceutical Co.,Ltd.
- 9.3.6. Panacea Biotec Ltd.
- 9.3.7. Biological E. Ltd.
- 9.3.8. Novartis AG
- 9.3.9. Shantha Biotechnics Ltd.
- 9.3.10. Serum Institute of India Pvt. Ltd.
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption
°ü·ÃÀÚ·á